bone marrow transplant chemotherapy
DESCRIPTION
BONE MARROW TRANSPLANT CHEMOTHERAPY. Jenny Li, Pharm.D. PGY2 Oncology Pharmacy Resident Wednesday, November 9, 2011. High Dose Therapy Rationale. DiPiro JT, et al. Pharmacotherapy 7 th ed. McGraw-Hill; 2008:2332. 2. Conditioning Regimens. Myeloablative Nonmyeloablative - PowerPoint PPT PresentationTRANSCRIPT
BONE MARROW TRANSPLANT BONE MARROW TRANSPLANT CHEMOTHERAPYCHEMOTHERAPY
Jenny Li, Pharm.D.PGY2 Oncology Pharmacy Resident
Wednesday, November 9, 2011
High Dose Therapy Rationale
DiPiro JT, et al. Pharmacotherapy 7DiPiro JT, et al. Pharmacotherapy 7 thth ed. McGraw-Hill; 2008:2332. ed. McGraw-Hill; 2008:2332. 22
Conditioning Regimens
Myeloablative
Nonmyeloablative
Radiotherapy/immunosuppression
3
Myeloablative Conditioning
Eliminate cancer in malignant disease
Make space for donor stem cells
Suppress recipient immune system from stem cell rejection in allo-SCT
4
Non-Myeloablative Conditioning
Graft-versus-tumor effect (GVT) from donor T-cells
Reduced-intensity conditioning (RIC) regimens
No eradication of host hematopoiesis and reversible myelosuppression
5
Non-Myeloablative Conditioning
DiPiro JT, et al. Pharmacotherapy 7th ed. McGraw-Hill; 2008. 6
Reduced Intensity Conditioning Regimen
Advantages• Decreased acute toxicity• Application to older and/or morbid
patients
Disadvantages• Loss/decrease in anti-tumor activity from
cytotoxic chemotherapy/radiation
7
Cytotoxic Agents
Alkylating agents• Cyclophosphamide• Busulfan• Melphalan• Carmustine• Carboplatin• Thiotepa
Antimetabolites• Cytarabine• Fludarabine
Topoisomerase II inhibitors• Etoposide
8
Common Conditioning Regimens
9
Cell-Cycle Activity of Cytotoxic Agents
DiPiro JT, et al. Pharmacotherapy 7th ed. McGraw-Hill; 2008:2094. 10
Properties of DNA
Image: US National Library of Medicine. Available at www.ghr.nlm.nih.gov. Accessed on 11/4/11.
From DNA to Protein
Image: Available at www.cytochemistry.net/cell-biology/ribosome.htm. Accessed on 11/4/11.
ALKYLATING AGENTSALKYLATING AGENTSCyclophosphamide
BusulfanMelphalan
CarmustineCarboplatin
Thiotepa13
Alkylating Agents Evolved from mustard gas used in WWI• Vesicant on skin/mucous membranes• Affects eyes/respiratory tract
Mechanism• Crosslink DNA strands• Prevents cells from replicating
Toxicities• Myelosuppression (dose-limiting)• Nausea/vomiting• Sterility• Secondary malignancies
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008 14
Cyclophosphamide
Dose 60mg/kg IV daily for 2 days
Activated by CYP450 to phosphoramide mustard and acrolein• Hemorrhagic cystitis 5-10%• Goal fluid intake >2-3L/day• Empty bladder several times daily (every 2 hours)• Uroprotection with mesna
100% cyclophosphamide dose over 24h, start 1h before CTX
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 15
Hemorrhagic Cystitis
Image: Takeuchi T, et al. Case Reports in Medicine 2010.
Cyclophosphamide Other toxicities• Alopecia• Skin/nail hyperpigmentation• Symptoms of inappropriate antidiuretic
hormone (SIADH)• Rhinitis/irritation of nose/throat• Cardiotoxicity and rare CHF
Monitor• Renal function/output/signs of bleeding
Regimens: BuCy, CyATG, CyFlu
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 17
Nail Hyperpigmentation
Images: www.accessmedicine.net and www.neurology.org. Accessed 11/4/11.
Busulfan Dose 0.8mg/kg IV every 6 hours for 16 doses
• Infuse over 2 hours
Dose 130mg/m2 once daily for 4 doses• Infuse over 3 hours
Drug Interaction• APAP ↓busulfan metabolism & ↑toxicity• Give APAP > 72 hours before busulfan
Toxicity • ↑ seizures reported (10%; range 2-40%)• Seizure prophylaxis with levetiracetam or phenytoin
Start 24 hours before, continue 24-48 hours after
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 19
Busulfan Other toxicities• Interstitial pulmonary fibrosis (busulfan lungs)• Other neurotoxicity (diziness, anxiety)• Skin/nail hyperpigmentation• Mucositis• Veno-occlusive disease
Monitor• Neurotoxicity (seizures, somnolence, lethargy
confusion)• Monitor drug level based on AUC
Regimens: BuCy, BuFlu
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 20
Busulfan Monitoring Goal AUC 900-1350
Sample draw times for every 6 hour dosing• Sample #1 (at END of infusion)• Samples #2 & #3 (15 minutes apart from END of infusion)• Sample #4 (3 hours from START of infusion)• Sample #5 (4 hours from START)• Sample #6 (5 hours from START)• Sample #7 (6 hours from START)
Draw 1-3mL blood in heparinized tube (always iced)• Centrifuge , remove and freeze plasma in labeled tube• Send to lab in Seattle with dry ice
Dose adjustments made after 6th dose • For daily dosing, 6 draws needed, adjust after 3rd dose
Seattle Cancer Care Alliance. Available at http://www.seattlecca.org/client/documents/Req_Q6-IV_Q24-IV_Busulfex_v2.pdf Accessed on 11/4/11. 21
Melphalan
Dose 140-200mg/m2 IV over 15-20 minutes for 1 dose
Must be given within 30 minutes of mixing
Toxicity• Hypersensitivity 2-10%• Severe diarrhea, nausea, vomitting• Mucositis
Prophylaxis with cryotherapy
• Shower twice daily
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 22
Melphalan
Monitor• GI toxicity• Hypersensitivity reactions
Bronchospasm, dyspnea, tachycardia, etc
Regimen: BEAM or by itself
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 23
Carmustine(BCNU)
Dose 300mg/m2 IV for 1 day
Toxicity• Cumulative pulmonary toxicity
>500mg/m2
• Renal toxicity at doses >1000mg/m2
• Facial flushing/discoloration (hang over) Contains 20% alcohol Administer slowly over 1-2h
• Hepatic toxicity with ↑LFT and bilirubinChu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 24
Carmustine(BCNU)
Monitor• Infusion site reaction (burning, pain)• Dyspnea, cough, fever
Can occur 1-3 months post transplant
Regimen: BEAM
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 25
Thiotepa
Mainly pediatric regimens Toxicities• Nausea/vomiting• Mucositis (dose-limiting)• Skin rash, erythema, hyperpigmentation• Neurotoxicity (confusion)
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 26
Carboplatin Dosing AUC or mg/m2
• CrCl: [(140 – age) x ABW] / (72 x SCr)] x 0.85 if female• IBW: (2.3 x inches > 60”) + (45.5 if F / 50 if M)• AdjWt if ABW > 1.25 x IBW: [(ABW-IBW) x 0.4] + IBW• Calvert formula:
Total dose mg = target AUC x (GFR + 25) Cap GFR = 125 ml/min
Toxicities• Nephrotoxicity (less than cisplatin)• Ototoxicity (less than cisplatin)• Mild nausea and vomitting• Neuropathy < 10% (less than oxaliplatin)
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 27
Carboplatin Example 55 year old female Weight = 90kg Height = 65 inches SCr = 1.2 AUC = 5
IBW = (2.3 x 5) + 45.5 = 57kg CrCl = [(140-55) x 57kg] / (72 x 1.2)] x 0.85• CrCl = 48ml/min
Dose = 5 x (48 + 25) = 365mg
28
ANTIMETABOLITESANTIMETABOLITES
CytarabineFludarabine
29
Cytarabine(ARA-C)
Pyrimidine analog, incorporated into DNA leading to chain termination
Dose 100mg/m2 over 1 hour every 12 hours x 8 doses (BEAM)• FLAG 2000mg/m2 daily for 5 doses
Toxicities at low dose• Myelosuppression• Transient ↑liver enzymes• Mucositis• Diarrhea
Toxicities at high dose• Cytarabine syndrome (fever, myalgia, bone pain, rash) • Chemical conjunctivitis• Cerebellar toxicity (> 40 years, abrnomal renal/hepatic function)• Pulmonary toxicity (ARDS)
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 30
Cytarabine(ARA-C)
Other toxicities• Hepatic dysfunction• Acute pancreatitis• Hand-foot syndrome at high dose
Regimen: BEAM
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 31
Fludarabine
5-monophosphate analog of cytarabine (prodrug)
Dose 20-40mg/m2 IV daily for 4 doses
Toxicities• T-cell depletion
PCP prophylaxis• Bactrim DS daily for three times weekly (MWF)
Antifungal prophylaxis (fluconazole) Antiviral prophylaxis (acyclovir)
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 32
Fludarabine
Other toxicities• Autoimmune effects
Hemolytic anemia, thrombocytopenia
• Fever, rash, hypersensitivity• Neurotoxicity (headache, solmnolence)• Peripheral neuropathy• Interstitial pneumonitis
Regimen: BuFlu, FluCy, FluTBI
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 33
TOPOISOMERASE II TOPOISOMERASE II INHIBITORSINHIBITORS
Etoposide
34
Topoisomerase II Inhibitors
Figure: Froelich-Ammon SJ, et al. J Biol Chem 1995;270:21429-32.
Etoposide Stabilizes topoisomerase II-DNA complex
(prevents unwinding)
Dose 100-200mg/m2 IV over 60min every 12 hours for 8 doses• Watch for cracking of plastic/tubing
Toxicities• Anaphylaxis (polysorbate 80)• Infusion related reaction (↓BP, flushing)
Infuse over > 1 hour, slower infusion if occurs• Hypersensitivity: bronchospasm, chills• Mucositis, diarrhea
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH, 20th ed. Lexi-Comp, Inc.;2011 36
Etoposide Other toxicities
• Secondary malignancies• Metallic taste during transfusion
Administration• Maximum concentration = 0.4mg/mL• Monitor for precipitation
Formulation• Phosphate salt more soluble• Maximum concentration = 20mg/mL
Regimen: BEAM, Carboplatin + Etoposide
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy Drug Manual. Sudburry, MA: Jones and Bartlett Pub.;2008Lacy CF, et al. Drug Information Handbook, 20th ed. Hudson, OH: Lexi-Comp, Inc.;2011 37
Common Conditioning Regimens
38
Dose-Limiting Toxicities
Chu E, DeVita VT. Physicians’ Cancer Chemotherapy. Jones and Bartlett Pub.;2008Lacy CF, et al. DIH. Lexi-Comp, Inc.;2011 39
Non-Hematologic Dose Limiting ToxicitiesBusulfan: hepatotoxicity; GI; pulmonaryCarmustine: pulmonary; hepatotoxicityCyclophosphamide: cardiotoxicityMelphalan: mucositis; GIThiotepa: neurotoxicity; mucositisCarboplatin: nephrotoxicity
Fludarabine: neurotoxicity
Etoposide: mucositis; GI
Total body irradiation: pulmonary toxicity; GI
BONE MARROW TRANSPLANT BONE MARROW TRANSPLANT CHEMOTHERAPYCHEMOTHERAPY
Jenny Li, Pharm.D.PGY2 Oncology Pharmacy Resident
Wednesday, November 9, 2011